These patterns specifically justify exploring PD-1/CTLA4 inhibitors for high-risk HCC, particularly when combined with evasion-countering approaches.While the TIDE results and checkpoint profiles suggest treatment potential, TIDE’s predictive framework originated from melanoma and NSCLC studies with limited HCC validation. This evidence concerns the gene CTLA4 and melanoma.